479 related articles for article (PubMed ID: 26307602)
1. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes.
Natarajan A; Mayer AT; Xu L; Reeves RE; Gano J; Gambhir SS
Bioconjug Chem; 2015 Oct; 26(10):2062-9. PubMed ID: 26307602
[TBL] [Abstract][Full Text] [Related]
2. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
[TBL] [Abstract][Full Text] [Related]
3. Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Mayer AT; Natarajan A; Gordon SR; Maute RL; McCracken MN; Ring AM; Weissman IL; Gambhir SS
J Nucl Med; 2017 Apr; 58(4):538-546. PubMed ID: 27980047
[TBL] [Abstract][Full Text] [Related]
4. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
5. Site-Specific Immuno-PET Tracer to Image PD-L1.
Wissler HL; Ehlerding EB; Lyu Z; Zhao Y; Zhang S; Eshraghi A; Buuh ZY; McGuth JC; Guan Y; Engle JW; Bartlett SJ; Voelz VA; Cai W; Wang RE
Mol Pharm; 2019 May; 16(5):2028-2036. PubMed ID: 30875232
[TBL] [Abstract][Full Text] [Related]
6.
England CG; Jiang D; Ehlerding EB; Rekoske BT; Ellison PA; Hernandez R; Barnhart TE; McNeel DG; Huang P; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):110-120. PubMed ID: 28821924
[TBL] [Abstract][Full Text] [Related]
7. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Imaging of the Programmed Death Ligand 1 by
González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
[TBL] [Abstract][Full Text] [Related]
9. Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
Wen X; Shi C; Zhao L; Yao L; Xu D; Lin X; Su X; Liu T; Zhuang R; Lin Q; Chen H; Guo Z; Zhang X
Nucl Med Biol; 2020; 86-87():44-51. PubMed ID: 32474281
[TBL] [Abstract][Full Text] [Related]
10. Construction and Preclinical Evaluation of
Tao J; Zeng Z; He C; Meng L; Zhou W; Ren Y; Ma X; Wang Z; Liu J; Li D; Zhang Q; Zhao C; Yang Z; Zhu H
Mol Pharm; 2024 Feb; 21(2):944-956. PubMed ID: 38270082
[TBL] [Abstract][Full Text] [Related]
11. Dosimetry Prediction for Clinical Translation of
Natarajan A; Patel CB; Habte F; Gambhir SS
Sci Rep; 2018 Jan; 8(1):633. PubMed ID: 29330552
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Xu M; Han Y; Liu G; Xu Y; Duan D; Liu H; Du F; Luo P; Liu Z
Mol Pharm; 2018 Oct; 15(10):4426-4433. PubMed ID: 30133286
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.
Natarajan A; Habte F; Gambhir SS
Bioconjug Chem; 2012 Jun; 23(6):1221-9. PubMed ID: 22621257
[TBL] [Abstract][Full Text] [Related]
14. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
15. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody.
Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J
J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743
[TBL] [Abstract][Full Text] [Related]
16. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.
England CG; Jiang D; Hernandez R; Sun H; Valdovinos HF; Ehlerding EB; Engle JW; Yang Y; Huang P; Cai W
Mol Pharm; 2017 Oct; 14(10):3239-3247. PubMed ID: 28825843
[TBL] [Abstract][Full Text] [Related]
17. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation and pilot clinical study of [
Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
[TBL] [Abstract][Full Text] [Related]
20. CD8
Seo JW; Tavaré R; Mahakian LM; Silvestrini MT; Tam S; Ingham ES; Salazar FB; Borowsky AD; Wu AM; Ferrara KW
Clin Cancer Res; 2018 Oct; 24(20):4976-4987. PubMed ID: 29967252
[No Abstract] [Full Text] [Related]
[Next] [New Search]